SCT has substantial intellectual property relating to the use of regenerative therapies for treating demyelinating diseases such as multiple sclerosis (“MS”). Scientific investigations by Dr. Samuel Weiss from the University of Calgary have characterized two potentially important therapeutic effects of prolactin on the central nervous system (“CNS”). In these published studies prolactin has been shown to act as both a neurogenic agent to increase the number of progenitor cells that mature into neurons and as an agent that promotes oligodendrocyte production and remyelination of the brain and spinal cord.

SCT was recently granted two key United States patents and one Australian patent for the use of prolactin in neurologic diseases based on the demonstrated insights into the effect of prolactin by Dr. Samuel Weiss. Moreover, the publication of those studies in high impact journals strongly support and validate the concept that prolactin may represent a potential new therapeutic platform for the treatment of white matter injury, and an impetus for a clinical program aimed at treating patients with MS.

Successful completion of a preliminary non-clinical study undertaken by Dr. V. Wee Yong, a Professor in the Departments of Oncology and Clinical Neurosciences at the University of Calgary, is expected to evolve into a clinical program to demonstrate efficacy in patients diagnosed with multiple sclerosis. The non-clinical results were announced September 11, 2009 at The 25^th Congress of the European Committee for the Treatment of and Research in Multiple Sclerosis by Dr. V. Wee Yong. Follow-on clinical study that will be led by Drs. Luanna Metz and Fiona Costello of the MS Clinic at the Foothills Medical Centre in Calgary, AB., is anticipated to begin in the second half of 2009. This study will be funded by an outside grant to the University of Calgary by the Canadian Stem Cell Network.